Flerie shareholders approved merger plan with Biosergen at EGM

• An extraordinary general meeting on Aug. 6, 2026 backed a merger plan for Flerie to absorb Biosergen.
• The plan sets an exchange ratio of 31 Biosergen shares for 1 new Flerie ordinary share, payable once the merger is completed.
• Shareholders also authorized the board to issue new ordinary shares, excluding pre-emption rights, to deliver the merger consideration.
• The resolutions approve the plan and financing mechanism; the merger itself remains subject to completion and is expected in Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Flerie AB published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.